Attached files
| file | filename |
|---|---|
| EX-10.18 - EX-10.18 - G1 Therapeutics, Inc. | gthx-ex1018_546.pdf |
| 10-K - 10-K - G1 Therapeutics, Inc. | gthx-10k_20171231.htm |
| EX-23.1 - EX-23.1 - G1 Therapeutics, Inc. | gthx-ex231_575.htm |
| EX-31.1 - EX-31.1 - G1 Therapeutics, Inc. | gthx-ex311_11.htm |
| EX-32.1 - EX-32.1 - G1 Therapeutics, Inc. | gthx-ex321_9.htm |
| EX-10.18 - EX-10.18 - G1 Therapeutics, Inc. | gthx-ex1018_546.htm |
| EX-31.2 - EX-31.2 - G1 Therapeutics, Inc. | gthx-ex312_10.htm |
Exhibit 32.2
CERTIFICATION UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of G1 Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2017 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: February 21, 2018 |
|
/s/ Barclay A. Phillips |
|
|
|
Barclay A. Phillips. |
|
|
|
Chief Financial Officer and Senior Vice President, Corporate Development |
|
|
|
(Principal Financial Officer) |